Extensive Perineural Invasion vs Nerve Caliber to Assess Cutaneous Squamous Cell Carcinoma Prognosis.
Journal
JAMA dermatology
ISSN: 2168-6084
Titre abrégé: JAMA Dermatol
Pays: United States
ID NLM: 101589530
Informations de publication
Date de publication:
18 Oct 2023
18 Oct 2023
Historique:
pmc-release:
18
10
2024
medline:
18
10
2023
pubmed:
18
10
2023
entrez:
18
10
2023
Statut:
aheadofprint
Résumé
Perineural invasion (PNI) is an adverse risk feature in cutaneous squamous cell carcinoma (CSCC) that affects patient prognosis and disease management. However, research comparing different PNI patterns on patient outcomes is limited. To compare 4 assessments of PNI in CSCC, their associations with poor outcomes, and implications for their inclusion in the Brigham and Women's Hospital (BWH) staging system. This retrospective cohort study was performed at a single tertiary care institution and compared 4 PNI assessments: nerve caliber, number of involved nerves per section, PNI maximal depth, and PNI location with respect to tumor. Patients with primary, localized, invasive CSCC with PNI diagnosed between January 1, 2000, and December 31, 2017, were identified via an electronic in-house database. Available pathology slides were secondarily reviewed by study authors. Relevant patient and tumor characteristics and outcomes were abstracted from the medical record. Data analysis was performed between September 6 and October 20, 2022. Risks of recurrence, disease-specific death, and a composite end point (any poor outcome) were calculated via multivariable stepwise Fine and Gray competing-risks regression. Considered revisions to the BWH staging system were assessed via receiver operating characteristic curves and test characteristics. This study included 140 patients with CSCC, with a mean (SD) age of 75.1 (11.2) years. More than half of the patients were men (93 [66.4%]), and most identified as White (132 [94.3%]). Of the 4 PNI assessments studied, only involvement of multiple nerves was associated with poor outcomes. Perineural invasion of 5 or more distinct nerves (extensive PNI [ePNI]) was independently associated with local recurrence (subhazard ratio [SHR], 13.83 [95% CI, 3.50-54.62]; P < .001), disease-specific death (SHR, 6.20 [95% CI, 1.59-24.21]; P = .009), and any poor outcome (SHR, 10.21 [95% CI, 2.88-36.15]; P < .001). A revised BWH staging system with substitution of ePNI for large-caliber PNI resulted in improved area under the curve and test characteristics compared with current BWH staging criteria that use nerve caliber as the measure of PNI. The findings of this cohort study suggest that ePNI is the best prognostic measure of PNI. Because ePNI obviated the need for a micrometer and had superior prognostic capacity to nerve caliber in this cohort, ePNI should be considered for inclusion in CSCC tumor staging. Inclusion of ePNI as a high-risk factor in CSCC staging systems may optimize patient selection for primary treatment and adjuvant interventions.
Identifiants
pubmed: 37851425
pii: 2810838
doi: 10.1001/jamadermatol.2023.3703
pmc: PMC10585586
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Références
Cancer. 2009 Aug 1;115(15):3379-91
pubmed: 19484787
J Am Acad Dermatol. 2005 Aug;53(2):261-6
pubmed: 16021121
Dermatol Surg. 2022 Feb 1;48(2):157-161
pubmed: 34889209
J Am Acad Dermatol. 2021 Jun;84(6):1708-1712
pubmed: 32781186
JAMA Dermatol. 2023 Jul 1;159(7):728-735
pubmed: 37285135
Otolaryngol Head Neck Surg. 2022 Oct;167(4):705-715
pubmed: 35133896
JAMA Dermatol. 2017 Aug 1;153(8):781-788
pubmed: 28678985
JAMA Dermatol. 2013 May;149(5):541-7
pubmed: 23677079
JAMA Dermatol. 2013 Jan;149(1):35-41
pubmed: 23324754
JAMA Dermatol. 2013 Apr;149(4):402-10
pubmed: 23325457
J Clin Oncol. 2014 Feb 1;32(4):327-34
pubmed: 24366933
Dermatol Surg. 2021 Apr 1;47(4):445-451
pubmed: 33795563
Dermatol Surg. 2009 Dec;35(12):1859-66
pubmed: 19889009
JAMA Dermatol. 2016 Apr;152(4):419-28
pubmed: 26762219
Radiother Oncol. 2016 Jul;120(1):81-6
pubmed: 27475277
J Am Acad Dermatol. 2019 Aug;81(2):548-557
pubmed: 30227190
Front Neurol. 2019 Sep 10;10:970
pubmed: 31551921
J Am Acad Dermatol. 2022 Jul;87(1):87-94
pubmed: 35364211